BackTable Urology
Ep. 206 Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines with Dr. Todd Morgan
Aditya Bagrodia
So we recently reviewed in one of our journal clubs, how do we kind of personalize this beyond PSA, doubling time, leasing score margins and so forth. And there seems to be some emerging data on biomarkers. Are you guys using that at all to inform timing, PSA levels, ADT, yes, no? Or do you think that's still kind of early phase?
0
💬
0
Comments
Log in to comment.
There are no comments yet.